Sun Pharma to acquire Concert Pharmaceuticals for US$576 mn

Concert is a late-stage biotechnology business that has finished evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata.

Hari Balakrishnan

This post is for paying subscribers only


Already have an account? Login